IDH1 and neoplasm: An alternative therapeutic strategy consists in exploiting, rather than reverting, the IDH-mut phenotype targeting the cellular epigenetic and metabolic vulnerabilities associated with the IDH mutations that persist, even at later stages of tumor development.